Combinatorial screening algorithm to engineer multiepitope subunit vaccine targeting human T-lymphotropic virus-1...

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Human T-lymphotropic virus (HTLV) is the first identified human retrovirus, responsible for severe conditions like HTLV-1 associated myelopathy and adult T-cell leukemia/lymphoma.
• HTLV infections affect millions globally, causing chronic spinal cord diseases and blood cancers.

Purpose of the Study:

• To design a multi-epitope subunit vaccine against Human T-lymphotropic virus (HTLV).
• To computationally evaluate the vaccine construct's immunogenic and expression potential.

Main Methods:

• A subunit vaccine was engineered by integrating B-cell, cytotoxic T-lymphocyte, and helper T-lymphocyte epitopes with adjuvants and linkers.
• The vaccine construct underwent 3D modeling, physicochemical property evaluation, molecular docking against Toll-like Receptor 3 (TLR-3), and in silico cloning for expression analysis.

Main Results:

• The designed vaccine construct demonstrated favorable physicochemical properties, predicted antigenicity, and non-allergenicity.
• Molecular docking and dynamics simulations indicated effective interaction with the TLR-3 immune receptor.
• In silico cloning confirmed the feasibility of expressing the vaccine in the pET28a(+) vector.

Conclusions:

• The in silico approach successfully generated a promising multi-epitope subunit vaccine candidate against HTLV.
• Further in vitro and in vivo studies are warranted to validate the vaccine's immunogenicity and efficacy.